Navigation Links
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Date:11/7/2007

romising therapeutic option for patients with unstable angina and non-ST elevation MI undergoing PCI ," said Rick Veltri, M.D., Group Vice President of Global Clinical Research, Cardiovascular and Metabolic Disease, Schering- Plough Research Institute. "With our global Phase III clinical development program underway, we are continuing to evaluate the potential for TRA as a novel agent in reducing the incidence of cardiovascular events with no incremental bleeding when added to standard of care in the treatment of patients with acute coronary syndromes or established vascular disease," added Veltri.

The results were presented today at the American Heart Association Scientific Sessions in Orlando, FL, in a session titled "Thrombin Receptor Antagonist Is a Selective, Potent Inhibitor of PAR-1 Activity With Predictable Pharmacokinetics."

About TRA-PCI

The Phase II TRA-PCI Trial was a multinational, randomized, double-blind, placebo-controlled dose-ranging trial assessing oral loading doses and maintenance doses of TRA. The trial enrolled 1,030 patients randomized to one of three oral loading doses of TRA (10 mg, 20 mg, 40 mg) plus standard of care (clopidogrel + aspirin) or placebo plus standard of care in a 3:1 ratio of active drug to placebo. Patients who received a TRA-loading dose and subsequently underwent PCI (n=573) were randomized to one of three oral daily maintenance doses of TRA (0.5 mg, 1.0 mg, 2.5 mg). Patients who received placebo were randomized to receive standard of care alone. The total duration of treatment was 60 days. Patients were followed for an additional 60 days post-treatment.

A secondary endpoint in a sub-study within the primary evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists relative to baseline.

TRA-PCI results were first presented at a late-breaking clinical trial session at the March 2007 Scientific Sessions of the American College of Cardiology/i2 Summit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... June 2, 2011 Goodwin Biotechnology, ... process development and GMP manufacturing of cell culture ... company focused on monoclonal antibody development with a ... discovery platform, announced a collaboration on the development ...
... Kendle (Nasdaq: KNDL ), a ... announced the appointment of Robert Shepard, MD, FACP, ...  Dr. Shepard is a leading authority on clinical ... of oncology research experience to Kendle. He will ...
Cached Medicine Technology:Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 2Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 3Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 2Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 3
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... Massage therapy improves general blood flow and alleviates ... by researchers at the University of Illinois at ... of print in the Archives of Physical ... improved vascular function in people who had not ... regardless of their level of physical activity. , ...
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... , SHENZHEN, China, Nov. ... http://www.beikebiotech.com ), China,s leading stem cell ... entered into an,agreement with Yokohama-based Biomaster Inc. ( ... technologies. Biomaster specializes in research,and commercialization of ...
... , COLUMBIA, S.C., Nov. 5 Companion Life Insurance ... facilitator to offer its dental policyholders preferred pricing on ... States. , Traveling abroad for credentialed dental care, also ... benefits. Prices at the international clinics average 60 to ...
... improvement, study finds, , THURSDAY, Nov. 5 (HealthDay News) -- ... make a good night,s sleep come more easily. , A ... that the odds of having disturbed sleep in the seven ... seven years before they stopped working. , Sleep improvements probably ...
... International Corporation (Nasdaq: PRXL ), a leading ... has established The Expert Office(TM) at PAREXEL. ... a single point of contact for clients to ... the Company,s leading medical, therapeutic area, regulatory, and ...
... ... published on GlucoStories.com , ... Pompano Beach, Fla. (PRWEB) November 5, 2009 --Today, American Diabetes Wholesale is asking ... will donate $3.00 for every story published on GlucoStories.com to diabetes organizations. The company’s ...
... ... for Thailand to become Asia,s medical hub is becoming a reality as Thailand continues to ... sector, ahead of the county,s GDP, the Tourism Authority of Thailand (TAT) and the Department ... lower medical treatments by 2010. , ...
Cached Medicine News:Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 2Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 3Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 4Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 2Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 3Health News:Without Job Stress, Retirees Sleep Better 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 3Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 4Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 5Health News:GlucoStories Donation Campaign Aims to Raise Diabetes Awareness and Money for Diabetes Causes 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: